These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 21217682)

  • 1. The ART of preventing HIV.
    Nat Med; 2011 Jan; 17(1):46-7. PubMed ID: 21217682
    [No Abstract]   [Full Text] [Related]  

  • 2. Integrating HIV prevention into practice.
    Mathers BM; Cooper DA
    JAMA; 2014 Jul 23-30; 312(4):349-50. PubMed ID: 25038352
    [No Abstract]   [Full Text] [Related]  

  • 3. Preexposure chemoprophylaxis for HIV prevention.
    Underhill K
    N Engl J Med; 2011 Apr; 364(14):1374; author reply 1374-5. PubMed ID: 21470023
    [No Abstract]   [Full Text] [Related]  

  • 4. Preexposure chemoprophylaxis for HIV prevention.
    Pittrof R; Sauer U; French P
    N Engl J Med; 2011 Apr; 364(14):1374; author reply 1374-5. PubMed ID: 21470022
    [No Abstract]   [Full Text] [Related]  

  • 5. Preexposure chemoprophylaxis for HIV prevention.
    Lee DH; Vielemeyer O
    N Engl J Med; 2011 Apr; 364(14):1372-3; author reply 1374-5. PubMed ID: 21470026
    [No Abstract]   [Full Text] [Related]  

  • 6. Preexposure chemoprophylaxis for HIV prevention.
    Sellier PO; Lafuente-Lafuente C; Roques P
    N Engl J Med; 2011 Apr; 364(14):1373; author reply 1374-5. PubMed ID: 21470025
    [No Abstract]   [Full Text] [Related]  

  • 7. Preexposure prophylaxis for HIV--where do we go from here?
    Cohen MS; Baden LR
    N Engl J Med; 2012 Aug; 367(5):459-61. PubMed ID: 22784041
    [No Abstract]   [Full Text] [Related]  

  • 8. Preexposure chemoprophylaxis for HIV prevention.
    Pimpinella G; Malgarini RB
    N Engl J Med; 2011 Apr; 364(14):1373; author reply 1374-5. PubMed ID: 21470024
    [No Abstract]   [Full Text] [Related]  

  • 9. Tenofovir DF and emtricitabine vs. zidovudine and lamivudine.
    Laessig KA; Lewis LL; Hammerstrom TS
    N Engl J Med; 2006 Jun; 354(23):2506-8; author reply 2506-8. PubMed ID: 16760455
    [No Abstract]   [Full Text] [Related]  

  • 10. Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco.
    Liu A; Cohen S; Follansbee S; Cohan D; Weber S; Sachdev D; Buchbinder S
    PLoS Med; 2014 Mar; 11(3):e1001613. PubMed ID: 24595035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. When is good good enough for HIV-1 prophylaxis?
    Buchbinder S
    Lancet Infect Dis; 2014 Nov; 14(11):1024-1025. PubMed ID: 25300861
    [No Abstract]   [Full Text] [Related]  

  • 12. Recent HIV-1 infection: to treat or not to treat, that is the question.
    Tossonian H; Conway B
    J Infect Dis; 2012 Jan; 205(1):10-2. PubMed ID: 22180623
    [No Abstract]   [Full Text] [Related]  

  • 13. Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for injecting drug users.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2013 Jun; 62(23):463-5. PubMed ID: 23760186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching STRATEGIES in HIV treatment.
    Schrijvers R; Debyser Z
    Lancet Infect Dis; 2014 Jul; 14(7):537-40. PubMed ID: 24908549
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA treads carefully with PrEP.
    Holmes D
    Lancet Infect Dis; 2012 Jul; 12(7):515-6. PubMed ID: 22930826
    [No Abstract]   [Full Text] [Related]  

  • 16. The British HIV Association/British Association for Sexual Health and HIV Position Statement on pre-exposure prophylaxis in the UK.
    McCormack S; Fidler S; Fisher M; ;
    Int J STD AIDS; 2012 Jan; 23(1):1-4. PubMed ID: 22362679
    [No Abstract]   [Full Text] [Related]  

  • 17. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
    Celum C; Morrow RA; Donnell D; Hong T; Hendrix CW; Thomas KK; Fife KH; Nakku-Joloba E; Mujugira A; Baeten JM;
    Ann Intern Med; 2014 Jul; 161(1):11-9. PubMed ID: 24979446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Boosting HIV treatment options: good news, new challenges.
    Cahn P; Sued O
    J Infect Dis; 2013 Jul; 208(1):4-6. PubMed ID: 23532095
    [No Abstract]   [Full Text] [Related]  

  • 19. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
    Sax PE; Tierney C; Collier AC; Fischl MA; Mollan K; Peeples L; Godfrey C; Jahed NC; Myers L; Katzenstein D; Farajallah A; Rooney JF; Ha B; Woodward WC; Koletar SL; Johnson VA; Geiseler PJ; Daar ES;
    N Engl J Med; 2009 Dec; 361(23):2230-40. PubMed ID: 19952143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial.
    Pozniak A; Markowitz M; Mills A; Stellbrink HJ; Antela A; Domingo P; Girard PM; Henry K; Nguyen T; Piontkowsky D; Garner W; White K; Guyer B
    Lancet Infect Dis; 2014 Jul; 14(7):590-9. PubMed ID: 24908550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.